Coronary disease & ACSRandomised controlled trial
Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease
- Randomised controlled trial (extended follow-up of the PRECOMBAT trial)
- 13 hospitals in Korea
- follow-up extended to at least 10 years
Authors' conclusion
Ten-year follow-up of the PRECOMBAT trial of patients with left main coronary artery disease randomized to PCI or CABG did not demonstrate significant difference in the incidence of major adverse cardiac or cerebrovascular events.
Study context
- Population
- Patients with unprotected left main coronary artery disease, Korea, 2004–2009median follow-up 11.3 years
- Participants
- 300 vs 300
- Comparison
- Percutaneous coronary intervention (PCI) with sirolimus-eluting stents vs coronary-artery bypass grafting (CABG)
- PCIn = 300
- CABGn = 300reference
- Primary endpoint
- MACCE:
- Death from any cause
- MI
- Stroke
- Ischemia-driven target-vessel revascularization
- Follow-up
- 10 years
Primary result
As reported in the abstract
Hazard ratio
1.25
95% CI 0.93–1.69
By group
PCI vs CABG
HR 1.25 (95% CI 0.93–1.69)
Further findings
| Outcome | PCI | CABG | HR (95% CI) | |
|---|---|---|---|---|
| Death, MI or stroke · 10 years · not significantly different | 18.2% | 17.5% | 1.00 (0.70–1.44) | |
| All-cause mortality · 10 years · not significantly different | 14.5% | 13.8% | 1.13 (0.75–1.70) | |
| Ischemia-driven target-vessel revascularization · 10 years · more frequent after PCI | 16.1% | 8.0% | 1.98 (1.21–3.21) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease. Circulation. Published 30 March 2020. doi:10.1161/circulationaha.120.046039
Summarised from the published abstract; every number is checked against it